i-Newsletter2023autumn

Knowledge Palette's gene expression profiling technology
contributes to new discoveries!

Research on New Corona Vaccine in Kawasaki CityIn July 2023, a press release was issued by Knowledge Palette, Inc., Kawasaki Physicians Association, Kawasaki
Rinko Hospital, and St. Marianna University School of Medicine, under the title "We have discovered a group ofgenes affected by multiple doses of corona vaccine”.
We interviewed Dr. Hiroki Danno, Co-founder, Representative Director & CEO and Dr. Masakazu Fukuda, Cofounder, Representative Director & CTO of Knowledge Palette, Inc., headquartered in King SkyFront, about
Knowledge Palette's areas of expertise, strengths, prospects, and the background leading up to the press release.

What does Knowledge Palette aim to contributeto health?
Knowledge Palette, Inc. was founded in 2018 and is a
startup company currently in its fifth year.
Th e co mpa n y is g ro win g th rou gh R&D a n dcollaborative research, and it is a life science andhealthcare company currently working on
approximately 20 projects. Our specialty is the world's
most accurate and fastest profiling of cellular big data.
Quartz-Seq2 (gene expression profiling) technology wasdeveloped at RIKEN in 2018. In 2020, we won firstplace in "gene detection performance, marker
identification performance" and "overall score" in aninternational benchmark by the Human Cell Atlas
project and were recognized globally as the gene
expression profiling technology with the highest
accuracy among 13 competing technologies. Currently,
as the next step, our R&D has the aim of controllingcells. Using highly accurate gene expression big data,
we are working to control quality at the cellmanufacturing stage by diagnose and control cellconditions. For cells used in regenerative medicine, inparticular not only is "cell growth" but also "cellproperties (safety and efficacy)" are important, andhigher quality and more stable cells are required.

What is the reason to issue a press release？
The research project presented at a press release wasmotivated by an information exchange event held at theKing SkyFront. While the emergency approval of thecorona vaccine has saved many lives, there is no historyof administering large amounts of RNA material into thebody. Therefore, we started this research. Nearly 200medical workers in Kawasaki City took blood samples
and analyzed samples before and after the second
vaccination, and before and after the third booster
vaccination.
As a result, long-term changes in genes related toimmunity were suggested. The results of this study werepeer-reviewed by experts and were published in theJournal of Medical Virology.
Knowledge of Palette's technology for transcriptome
analysis (visualization of gene and-cell function) led tothe success of this study and has motivated ongoingresearch.

Dr. Fukuda, CTO and Dr. Danno, CEO
Click here for news releaseCellab Healthcare Service CO., LTD. began cell manufacturing contract business
In June 2023, Cellab Healthcare Service CO., LTD., a wholly owned subsidiary of DAI-DAN CO., LTD. began a cellmanufacturing contract business at the cell culture and processing facility "Cellab Tonomachi”.
The company obtained a manufacturing license for regenerative medicine products
at Cellab Tonomachi in May 2023 and has acquired an exclusive license to
manufacture clinical trial products and the non-exclusive license to manufacturecommercial products for the cancer immune cell therapy product “GAIA-102 (NKlike cells)”. This is currently undergoing clinical research by GAIA Biomedicine, astart-up company from Kyushu University, and has started contract manufacturingof GAIA-102 clinical trial product. With this contract, the DAI-DAN CO., LTD.
Group will make a full-scale entry into the cell manufacturing contract business andthus expand its share of the market.
Cellab Tonomachi
Click here for Cellab Healthcare Service news release

NANOEGG® Research Laboratories, Inc.
began collaborative research using “Nano capsule Technology”
In August 2023, NANOEGG® Research Laboratories, Inc. began collaborate research of medical ophthalmic products
using their own “nano capsule technology” with Rohto Nitten Co., Ltd of the ROHTO PharmaceuticalGroup.
Spherical formulations with a particle size of several 10 nm (1 nm = one billionthof a meter) are called “nano capsules” by NANOEGG and they have thetechnology to achieve a drug content of nearly 100% in these capsules.
In addition, by coating the nano capsules with a thin film of amorphous inorganic
material, a mechanism (drug delivery system) is realized in which the drug inside
the capsule is gradually released. In this collaborative research, NANOEGG aims
to apply “nano capsule” technology for medical ophthalmic products and eyedrops.
Click here for NANOEGG news release

Electron micrograph photo of nano capsule

Visit by the Embassy of the Kingdom of the Netherlands and the Dutch delegationof the Regenerative Medicine Crossing Borders
On October 13, 2023, the members of the Embassy of the Kingdom of the Netherlands and the Dutch delegation of theRegenerative Medicine Crossing Borders (RegMed XB) visited King SkyFront. The purpose of their visit was to findout about regenerative medicine initiatives in Japan and explore collaborative
business opportunities through interaction with local institutions.
They visited the open lab developed by the Kanagawa Prefectural Government
through public-private partnership in the Life Innovation Center and theanalytical instruments for in-house displays in Shimadzu Tokyo Innovation
Plaza.
They also visited the division of medical devices National Institute of HealthSciences(Director, Eiichi YAMAMOTO, Ph.D.) and the division of cell-based
therapeutic products National Institute of Health Sciences(Director,Satoshi YASUDA, Ph.D.) and active discussions took place.

The event “Building Startup Community in King SkyFront” was hosted
by iCONM with BioLabs“iCONM in collaboration with BioLabs”, an incubator forbiotech startups, held a networking event on October 12, 2023.
With a lab-tour of iCONM, they had a panel discussion with 4
panelists including Dr. Johannes Fruehauf, CEO of our partner “BioLabs”, anddiscussed on “What community helps startup’s growth”. 60+ participants
including biotech-startups, VCs, and other ecosystem builders joined thediscussion and expanded their networks.
Click here for Linkedin

About a comb-structured mRNA vaccine
The worldwide outbreak of the new coronavirus attracted
attention to “mRNA vaccine”, the first preventive vaccine inhuman history, which can be developed in a short period andimmediately applied to the newly generated virus. It was thesubject of this year‘s Nobel Prize. This vaccine eliminates virusesby producing a large number of antibodies that recognize andeliminate the spike proteins on the surface of the virus. However,antibodies are ineffective against large foreign substances (whichthe body wants to eliminate) such as infected cells and cancer
cells. Prof. Satoshi Uchida, iCONM’s Principal Research
Scientist (Professor of Tokyo Medical and Dental University) andhis group have developed a therapeutic vaccine that can eliminate
cancer cells by comb-structured mRNA, and demonstrated its
effectiveness in a mouse model of malignant melanoma. The
results were published in the online version of the Proceedings ofthe National Academy of Sciences of the United States ofAmerica (PNAS) on July 10, 2023.

Update of the King SkyFront pamphlet and website for the2023 – 2024 edition
We have updated the King SkyFront pamphlet and website for the2023 – 2023 edition.
Please visit the website at the following link for more information.
Click here King SkyFront website

Click here for PNAS website

For subscription
Keep you updated with the latest news from KINGSKYFRONT
Please apply here for subscription. i-Newsletter comesout quarterly and free subscription.
https://ws.formzu.net/fgen/S11051741/
Date of issue: November 2023
Publisher: TONOMACHI LifeScience Cluster Division
Kawasaki Institute of Industrial Promotion
Mail：pr-ksfcl@kawasaki-net.ne.jp